陈冯富珍怒了:埃博拉肆虐40年,制药商干嘛去了

  • 陈冯富,埃博拉病毒
  • 中国日报网

11月3日,联合国世界卫生组织总干事陈冯富珍对目前埃博拉病毒疫苗研制现状提出尖锐批评,称研发商是因为埃博拉病毒多在非洲贫穷地区蔓延,生产无利可图而怠于研制。此外,联合国前秘书长也批评发达国家事不关已、高高挂起。

据英国《独立报》报道,陈冯富珍11月3日向世卫组织非洲地区委员会表示:“埃博拉病毒出现已近40年,为什么现在医生依然没有有效的疫苗及治愈办法?因为埃博拉病毒长期以来多在非洲贫穷地区蔓延,药企几乎没有研发动力,因为这个行业以利益为导向,不会投资无法获得回报的市场。”

而在最近数月,几种埃博拉病毒疫苗迅速进入研制阶段,而这在通常情况下需耗时十年以上,不过前景最好的疫苗测试期也不会早于明年底完成。

自1976年首次被发现以来,埃博拉病毒已前后爆发过20余次,如今这次爆发甚于以往任何一次,目前已造成西非地区5000人不治身亡,并已突破了美国医疗防线,于美国本土出现了9例埃博拉病患,其中一人死亡。

目前由葛兰素史克公司研制的疫苗ChAd3正在牛津大学詹纳研究所进行安全试验,这个由英国维康基金会和英国政府赞助280万英镑(约合人民币2739.7万元)的研发项目预计明年初将生产出10000剂强力有效疫苗,一旦通过安全试验,将会首先被应用在于西非抗击埃博拉病毒一线的医护人员,以进行效果测试。

报道称,当天陈冯富珍还批评说:“世卫组织长期以来呼吁为贫穷国家地区研发疫苗和投资建设医疗系统,但是一直被置若罔闻,因此才导致了现在的情况,全世界每天都能在黄金时段的新闻中,感受到对埃博拉疫情的恐慌。“

据世界卫生组织最新公布的数据显示,自今年3月暴发以来,目前全球确认或疑似埃博拉病毒感染者已经超过13567人,其中4951人死亡;而世界范围内,受埃博拉影响的国家已经达到8个。

安南:如果这场危机发生在其他地区,应对它的态度可能完全不同

据英国广播公司(BBC)10月16日报道,联合国前秘书长安南罕见发声,对发达国家的不作为表示“沉痛且失望”。安南提到,埃博拉疫情在西非地区早已形势严峻,但“国际社会直到病毒蔓延到美国和欧洲才真正醒悟过来”,“我失望,国际社会没有更迅速地行动,如果这场危机发生在其他地区,应对它的态度可能完全不同……我要批评那些有能力的国家”。

安南还为世卫组织近来所受的应对不力指责“抱不平”,称这一机构早已意识到疫情的严重性,但只能依靠国际社会的支持和援助才能有效协调疫情应对。

This link:http://www.chemcd.com/news/7074.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.